Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
1 hedge funds and large institutions have $10.8M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2023 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less capital invested
Capital invested by funds: $11.1M → $10.8M (-$284K)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LIP
Liontrust Investment Partners
London,
United Kingdom
|
-$4.91M |
BHVN Hedge Fund Activity: Q2 2023 in Review
1 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2023, worth a combined $10.8M — down 2.6% from $11.1M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BHVN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Liontrust Investment Partners, exiting entirely with an estimated $4.91M sold.
- 1 institutional investor held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2023, down from 2 in Q1 2023.
- Funds reported $10.8M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2023, down 2.6% quarter-over-quarter.
- 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2023 and 1 closed out, a net change of -1 holder.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2023 was Liontrust Investment Partners, an estimated $4.91M sold.
Based on aggregated 13F filings for Q2 2023.